Physician profile
Amanda Ching-Wun Cheung
NPI 1548585193
$64,336.39
in general payments reported to CMS, 2019-2025
8 companies · $44K in 2025
The $44K reported for 2025 was more than what 84% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.70 · 2023: $3,863 · 2024: $16K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Consulting Fee: $18K · Honoraria: $6,900 · Travel and Lodging: $3,795 · Food and Beverage: $3,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,714.88 |
| Consulting Fee | $17,838.75 |
| Honoraria | $6,900.00 |
| Travel and Lodging | $3,795.04 |
| Food and Beverage | $3,050.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $52,372.98 | 2022-2025 | Wegovy |
| Orphalan INC | $7,181.21 | 2023-2025 | Cuvrior |
| Madrigal Pharmaceuticals | $4,044.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Eton Pharmaceuticals, INC. | $500.00 | 2025 | Galzin, Carglumic Acid, Nitisinone |
| Mallinckrodt Hospital Products INC. | $110.93 | 2025 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $68.30 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.36 | 2023 | Xifaxan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.